Reduced hippocampal volume has been reported in depression and may be involved in the aetiology of depressive symptoms and vulnerability to depressive relapse. Neuroplasticity following antidepressant drug treatment in the hippocampus has been demonstrated in animal models but adaptive changes after such treatment have not been shown in humans. In this study, we determined whether grey matter loss in the hippocampus in depression (1) is present in medication-free depressed (2) changes in response to antidepressant treatment and (3) is present as a stable trait in medication-free remitted patients. Sixty-four medicationfree unipolar depressed patients: 39 currently depressed and 25 in remission, and 66 healthy controls (HC) underwent structural magnetic resonance imaging in a cross-sectional and longitudinal design. Thirty-two currently depressed participants were then treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring plasma citalopram concentration. We measured regional variation in grey matter concentration by using voxel-based morphometry-Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra. Patients with current depression had bilaterally reduced grey matter in the hippocampus compared with HC and untreated patients in stable remission with the latter groups not differing. An increase in grey matter was observed in the hippocampus following treatment with citalopram in currently depressed patients. Grey matter reduction in the hippocampus appears specific to the depressed state and is a potential biomarker for a depressive episode.
INTRODUCTION
Magnetic resonance imaging (MRI) has been widely used to investigate unipolar major depression and structural brain abnormalities in the temporolimbic-frontal-caudate network have been described with heterogeneous results. 1 Brain morphometric anomalies have been described in depression in a number of studies with a region of interest (ROI) and voxelbased morphometry approach (VBM). These abnormalities include volumetric reductions in frontal cortex, orbitofrontal cortex, cingulate cortex, ventral striatum, thalamus, hippocampus and pituitary enlargement. [2] [3] [4] In treatment-free patients, grey matter loss has been documented in superior temporal gyrus and parahippocampal gyrus whereas grey matter reduction in the amygdala has been linked with the presence of co-morbid anxiety. 4 However, morphometric reduction in the hippocampus is the most replicated finding described in the MRI literature in depression, with both a ROI approach 2 and VBM. [5] [6] [7] [8] [9] Hippocampal damage resulting from prolonged exposure to stress-induced glucocorticoid release is considered an important contributor to the pathogenesis of depression. Data from preclinical and postmortem studies suggest that prolonged stress can induce hippocampal neuronal loss, 10 pruning of apical dendrites in the CA3 hippocampal region, 11 decreased dentate gyrus neurogenesis 11 and loss of glial cells. 12 The prevalence and magnitude of hippocampal abnormalities, dependent on clinical and demographical variables such as pharmacological treatment and remission, have varied in clinical studies. Mostly cross-sectional studies have investigated patients undergoing pharmacological treatment and less frequently unmedicated samples. 5, 9, [13] [14] [15] [16] [17] According to post-mortem and animal model studies, most antidepressants upregulate neurotrophin expression, 18 stimulate adult hippocampal neurogenesis within the time frame consistent with response to antidepressant treatment [19] [20] [21] and protect against grey matter loss. 22 Evidence for the acute modulatory effect of antidepressants on hippocampal structure in currently depressed from longitudinal study is lacking. 14, 17, 23 However, grey matter increase in the hippocampus of medicated currently depressed achieving remission over a 3-year period suggests that hippocampal atrophy is state dependent. 24 In this study, we aimed to investigate morphometric changes in depression in relation to medication responsiveness and clinical improvement by using VBM improved with the 'Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra' (DARTEL). Voxel-based morphometry offers the advantage of an unbiased evaluation of volumetric grey matter differences without identification a priori of hypothesised regions of interest. 25 We combined a cross-sectional and longitudinal design to test the hypotheses that grey matter is reduced in the hippocampus in depression and that hippocampal grey matter increases with clinical response following antidepressant treatment. We predicted that unmedicated currently depressed patients would show hippocampal grey matter reduction compared with healthy controls (HC) or untreated patients in stable remission, which would increase only in those remitting on antidepressant treatment.
MATERIALS AND METHODS Participants
Sixty-four medication-free patients meeting DSM IV criteria for unipolar major depression, 39 currently depressed (cMDD) and 25 in remission (rMDD), were recruited and matched with 66 HC as shown in Table 1 (see  Supplementary Information for details of medication history and drug-free  period) . Patients and controls were screened with the Structured Clinical Interview for DSM-IV Disorders. 26 Severity of illness was established by using the Montgomery Åsberg Depression Rating Scale 27 and the 7-item Clinical Anxiety Scale (CAS) adapted from the Hamilton Anxiety Rating Scale. 28 Inclusion criteria for cMDD were an acute episode of unipolar major depression and a score X20 on the MÅDRS. Patients in remission were included if they had experienced at least one past episode of unipolar major depression and scored p10 on the MÅDRS. Concurrent comorbid Axis I psychiatric disorder and primary cluster A or B Axis II disorders were excluded. Exclusion criteria for all participants comprised any unstable medical condition, neurological disorders, history of significant head trauma, lifetime history of substance or alcohol misuse disorders, any contraindication to MRI scanning and a positive family history for psychiatric disorders in HC. Intelligence quotient was assessed with the Quick Test. 29 Recruitment was conducted at the University of Manchester and all participants gave informed consent and were paid for their participation. The study was approved by the local research ethics committee and conformed with the Declaration of Helsinki. 30 Longitudinal study and antidepressant drug treatment Thirty-six cMDD participants were treated with citalopram and returned for a second MRI scan after 8 weeks. A group of 15 HC also underwent two MRI scans with an 8-week interval to control for potential order and testretest effects. After the initial assessment, baseline MRI images (visit 1, V1) were acquired before commencing treatment for the cMDD group. Citalopram hydrobromide 20 mg was prescribed and the dose could be increased to 40 mg after 4 weeks of treatment according to response. All cMDD participants received a stable dose of citalopram for at least 2 weeks before the second scan (visit 2, V2). Citalopram adherence was confirmed by measurement of plasma citalopram. Samples were collected at the time of the second MRI scan. Participants in whom citalopram could not be detected were excluded from the analyses (Supplementary Information).
Data acquisition and image analysis Images were first visually checked for scanner artefacts and anatomical anomalies. Pre-processing was done using DARTEL for VBM in SPM8 31 and Matlab R2008a (MathWorks, Natick, MA, USA) where T1-weighted images were aligned and segmented before being imported into the DARTEL toolbox. Using DARTEL, two separate templates were generated for the cross-sectional and longitudinal studies. In DARTEL, each participant's segmented grey matter image was rigidly aligned, then warped to fit the grey matter probability map in Montreal Neurological Institute space using spatial normalisation routines in SPM. Images were modulated to adjust for volume changes during normalisation, warped and smoothed with an isotropic Gaussian kernel of 8 mm. The 'imcalc' function was adopted to create an average of the grey matter images to create a binary mask that includes all voxels with more than 10% probability on average of being grey matter. 32 Differences between groups were investigated using the general linear model, with total grey matter volume, extracted with the Easy-volume tool, 33 included as a covariate of no interest. The longitudinal study comprised of the cMDD, treated with citalopram, and a subgroup of HC participants receiving two MRI scans 8 weeks apart. Grey matter changes between visits (V1-V2) were investigated for cMDD and HC separately. We first determined whether currently depressed patients showed differences in regional grey matter compared with HC. We then determined whether differences were seen in the same regions in a group of patients in stable remission from depression and whether the changes reversed with remission over the course of antidepressant treatment. Given that it was not possible to do a three-way comparison in SPM8, for all the possible paired group comparisons at baseline, whole-brain analysis was conducted at the cluster level by adopting nonstationary cluster-size interference 34 with a height threshold of Po0.025 and a nonstationary-corrected cluster threshold of Po0.05. This method corrects for the heterogeneous smoothness in VBM analysis and allows for valid cluster-level interference. 35 The WFU PickAtlas [36] [37] [38] [39] was used to identify regions showing significant group differences. Masks were then created for each anatomical region to investigate group differences in grey matter within these regions and changes over time in the longitudinal study. Nonstationary cluster inference was again used for each anatomical mask with the threshold for statistical significance Bonferroni corrected in relation to the number of regions tested. We used a subtraction of the grey matter images from visit 2 compared with visit 1 per participant in the longitudinal study to test for any morphometric changes following treatment and improvement. Furthermore, to test our hypothesis that the morphometric changes were specific to the hippocampus, an additional small volume-corrected VBM analysis with nonstationary cluster statistics was conducted in the bilateral hippocampus. Grey matter changes in cMDD in the hippocampus were also investigated in relation to clinical variables within these regions, including severity of depression and anxiety symptoms and time spent unwell before treatment with analyses of correlations in SPM with total grey matter volume as a variable of no interest. Table 1 . Groups were matched with respect to all the variables considered including sex, mean age, intelligence quotient, number of episodes and age of onset. All participants were right handed apart from four cMDD and matched HC. There were no significant global volumetric differences in total grey matter between groups (Table 1 and Supplementary Information). 
RESULTS

Details of clinical characteristics are displayed in
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Cross-sectional study Voxel-wise analysis indicated that cMDD had less regional grey matter than the HC bilaterally in a cluster extending from the hippocampus and parahippocampal gyrus into the fusiform gyrus/ inferior temporal gyrus and ventral striatum. In comparison with remitted depressed, bilateral grey matter reduction in the cMDD included the hippocampus and parahippocampal gyrus extending into the left fusiform gyrus/inferior temporal gyrus (Table 2 and Supplementary Figure 1) . The average grey matter reduction in cMDD in the hippocampus and parahippocampal gyrus cluster was 24-29% vs HC and 17-27% vs rMDD (Figure 1 ). There were no significant grey matter differences between rMDD and HC.
Longitudinal study Whole-brain analysis. 
Grey matter increase in the cMDD group between the two scans in the hippocampus was 2% on the left and 2.4% on the right. There were insufficient non-remitters, particularly those with poor or lack of response to be able to compare remitters vs non-remitters in this sample.
ROI analysis in the hippocampus. For the remitters, comparing V2 with V1, the small volume correction for the hippocampus revealed significant grey matter gain bilaterally (L: Figure 2) .
Correlations
Correlational analyses in cMDD participants demonstrated a significant negative relationship between grey matter volume and duration of untreated depressive symptoms both at whole brain and small volume correction in the hippocampus (Figure 3) , 
DISCUSSION
In this cross-sectional and prospective study of currently and remitted depressed subjects, we identified grey matter reduction in the hippocampus in cMDD with grey matter gain in the same structure following successful antidepressant treatment and remission. We also demonstrated clusters of grey matter decrease in parahippocampal gyrus, inferior temporal gyrus, fusiform gyrus and ventral striatum in unmedicated currently depressed participants. Selective grey matter increase in the hippocampus following acute treatment and remission to our knowledge has not previously been reported in unmedicated depressed subjects prospectively treated with antidepressants although a small study has reported hippocampal volume increase comparable to that seen in our study after successful treatment with electroconvulsive therapy. 40 Lai et al. demonstrated grey matter loss in the hippocampus in cross-sectional studies of unmedicated depressed patients 17, 41 but found that 6-week treatment with duoloxetine did not affect grey matter deficits in depressed patients with co-morbid panic disorder. 17 In a study of the anterior cingulate cortex, Chen et al. observed that greater grey matter volume predicted greater clinical improvement after 8-week treatment with fluoxetine.
14 Our results are consistent with preclinical studies showing that neuroplastic changes in the hippocampus following antidepressant treatment occur early and may be neuroprotective. [18] [19] [20] Antidepressants have been shown to increase brain-derived neurotrophic factor (BDNF) levels in rats undergoing early-life maternal separation, in the dentate gyrus and the CA3 region of the hippocampus, 42 and antagonise stressrelated downregulation of BDNF. 43 This effect has been shown to be mediated by increasing cyclic adenosine monophosphatedependent phosphorylation in post-mortem studies 44 and cyclic adenosine monophosphate response element-binding protein (CREB) mRNA levels in the CA1, CA3 and dentate gyrus regions of the hippocampus 23, 45 and associated with hippocampal neuronal sprouting and neurogenesis. 23 Human studies suggest that low circulating concentrations of BDNF are associated with the depressive state in unmedicated patients and that remission leads to normalisation following antidepressant treatment. 46 Antidepressants may therefore contribute to hippocampal grey matter increase in the presence of remission. This finding is in agreement with current evidence of grey matter gain in the hippocampus of medicated depressed patients when remission occurred in a follow-up study over 3 years. 24 It is also largely consistent with a recent longitudinal study by Schermuly et al. 47 reporting morphometric increase in the hippocampus in a small group of depressed participants who responded to antidepressant treatment, although their findings were confined to the posterior hippocampus. Our findings also support previous evidence that longer duration of untreated depressive symptoms before commencing treatment with antidepressants is associated with volumetric reduction in the hippocampus 48 suggesting an ongoing 'toxic' effect of the depressive state on hippocampal neurones or neuropil. In our analysis of remitted medicated vs remitted unmedicated patients, we found reduced grey matter in the parahippocampal gyrus in the remitted medicated patients although mean grey matter volume in this region in the medicated participants was not significantly different to healthy individuals. This suggests the possibility that neuroplastic phenomena occur early in the hippocampus and may progress further in the parahippocampal gyrus in sustained remission and may be distinguished from functional changes. 49 Similar to the hippocampus, parahippocampal neuroplasticity may be modulated by BDNF as this region has been associated with smaller volumes in healthy individuals carrying the BDNF Val66Met genotype, resulting in diminished BDNF secretion. 50, 51 The relationship between antidepressant treatment and clinical improvement cannot be, however, clearly distinguished in this study because the large majority of patients achieved full remission and even most non-remitters had improved significantly.
We found clusters of reduced grey matter in currently depressed but not in remitted or HC in the hippocampus/ parahippocampal gyrus, fusiform gyrus/inferior temporal gyrus and ventral striatum, components within the extended visceromotor network implicated in mood regulation, 1 and believed to be associated with impairment of effortful regulation of emotional behaviour. 52 Our results are largely in agreement with VBM crosssectional comparisons of depressed patients vs controls that showed similar reduction in medicated 8, [53] [54] [55] [56] [57] [58] [59] and unmedicated 9, 16, 17, 41 patients. In this study, cMDD participants were unmedicated and grey matter reduction in the temporal regions and parahippocampus have been shown to be the expression of medication-free status and a relatively recent onset of depression. 4 The cross-sectional comparison of currently depressed with remitted and healthy participants demonstrates that grey matter loss in the 'dorsal network' may not be present in sustained remission. Salvadore et al. (2010) 15 adopted a similar cross-sectional design and recruited unmedicated depressed patients, remitted depressed and HC, and demonstrated reduced prefrontal cortical grey matter in those currently depressed in comparison with controls localised in the dorsoanterior-lateral/dorso-medial prefrontal cortex and compared with remitted depressed subjects in dorso-anterior-lateral/ventrolateral prefrontal cortex, anterior cingulate cortex, precuneus and inferior parietal lobule. They also reported greater grey matter in those remitted from depression in comparison with controls in pregenual and subgenual anterior cingulate cortex, the left frontal polar cortex, right inferior parietal lobule and the superior temporal gyrus. 15 However, in contrast to Salvadore et al. (2010), we included a clinically homogeneous sample of depressed patients. Participants in sustained remission were characterised by an episodic rather than chronic course of illness, which may account for some of the differences in the results. We did not find reduction in the subgenual and anterior cingulate cortex, possibly because it has been primarily identified in affected subjects with familiar aggregation of illness and may be the expression of a specific illness phenotype. 1 Alternatively, grey matter loss in the anterior cingulate cortex may be the expression of more chronic type of illness and/or medicated status. 4 Moreover, volumetric reduction in the prefrontal areas appears to be inconsistent in VBM and ROI studies 2, 7, 13, 24, [57] [58] [59] [60] [61] and may depend on the clinical sample investigated including variance in genetic vulnerability, early abuse, chronic stress, treatment status and methodological differences explaining at least in part differences in the results.
Strengths of this study include the large sample of depressed and remitted patients, measures repeated in the same patients before and after treatment and the control for nonspecific repetition effects by testing HC over the same interval. The study does, however, have a number of limitations. Currently depressed participants included in this study experienced symptoms in the moderate range and we did not include more severely ill patients who may have shown a different pattern of abnormality. Although depressed patients in the longitudinal and cross-sectional studies were recruited according to the same criteria and matched on clinical and demographic variables, patients might have differed on other variables, for example, length of remission, illness severity, and so on. This might explain discrepancies with other studies, for example, Gerritsen and others that demonstrated smaller hippocampal volumes in remitted depressed patients vs HC. 62 Moreover, the design controls for retest effects but it cannot control for the interaction between group and retest, for example, those with reduced hippocampal volume may be most likely to show a degree of change as a function of time. We were not able to investigate the relationship between morphometric changes in the hippocampus, stress hormones and hypothalamo-pituitaryadrenal axis activity. This is an important question as there is evidence from animal studies that antidepressants promote neurogenesis in the hippocampus to improve stress response regulation 63 and that neurogenesis in the hippocampus appears critical in controlling HPA axis activity in animal models of depression. 64 We also cannot be certain that the same results would have been obtained using other analysis techniques (for example, an ROI approach); however, recent studies have found that manual tracing or automatic segmentation produced similar results to VBM with DARTEL normalisation, although the latter appears more sensitive in detecting differences. [64] [65] [66] Cluster analysis offers the great advantage of correcting for nonisotropic smoothness of VBM data but presents limitations in terms of multiple group comparisons. 35 Finally, it is important to acknowledge that preclinical and clinical data supporting neuroplastic changes in the hippocampus following antidepressant treatment and relationship with BDNF levels are not entirely consistent. 67 Although neuronal cell loss (and cell proliferation/survival following treatment) provides one explanation for our findings, the physiological properties of the grey matter measured with VBM are not yet established and the changes measured in this study could be a nonspecific finding. The implications of the findings for vulnerability to depression and for the effect of treatment itself are uncertain without studies in relatives of patients with depression, studying medicated and unmedicated remitted depressed patients at the same distance in time from a depressive episode and in relation to other treatments. For instance, an increase in choline-containing compounds signal in the hippocampus has been described in depression following treatment with electroconvulsive therapy. 68, 69 This suggests that changes in the hippocampus may be susceptible to other forms of treatment. Alternatively, the increase in hippocampal volume could represent a marker of current symptom state irrespective of the mechanism of drug action. A larger sample of patients who failed to remit on treatment would also have enabled us to separate the role of drug effects from effects of remission more clearly. Finally, a placebotreated group of depressed patients would have more effectively addressed causality.
Although it is not possible to exclude the possibility that hippocampal reductions may precede depression onset, for example, genetic factors may be responsible for a smaller hippocampus, or the extent other factors confer vulnerability to depression, for example, history of abuse and stressful early life events, this study offers evidence of hippocampal grey matter reduction in depression as the expression of a 'state' effect that can begin to reverse rapidly with successful treatment and may therefore be a target biomarker for early intervention. Further work is needed to determine how specific this is for unipolar depression compared with other psychiatric disorders, such as bipolar depression, 70, 71 and the role of morphometric changes in relation to therapeutic approaches.
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